Results 11 to 20 of about 34,488 (237)

Production of β-Lactamase Inhibitors by Streptomyces Species [PDF]

Antibiotics, 2018
β-Lactamase inhibitors have emerged as an effective alternative to reduce the effects of resistance against β-lactam antibiotics. The Streptomyces genus is known for being an exceptional natural source of antimicrobials and β-lactamase ...
Daniela de Araújo Viana Marques, Suellen Emilliany Feitosa Machado, Valéria Carvalho Santos Ebinuma, Carolina de Albuquerque Lima Duarte, Attilio Converti, Ana Lúcia Figueiredo Porto   +5 more
doaj   +2 more sources

Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates [PDF]

, 2022
With the emergence and rapid spreading of NDM-1 and existence of clinically relevant VIM-1 and IMP-1, discovery of pan inhibitors targeting metallo-beta-lactamases (MBLs) became critical in our battle against bacterial infection.
Winnie Prosise (14231582), Shu-Wei Yang (2351068), Alex G. Therien (10156446), Weidong Pan (1427614), Giovanna Scapin (1427611), Christine Yang (149071), Li Xiao (307908), Jianping Pan (5473910), Amy Flattery (1349508), Thierry Fischmann (1586191), Alexander Pasternak (161010), Mihirbaran Mandal (2026381), Priya Dayananth (1720108), Todd W. Mayhood (2383978), Alexei V. Buevich (1433287), Katherine Young (526710), Jim Tata (1463734), Carrie Markgraf (14231588), Jacqueline D. Hicks (2335909), Nicholas Murgolo (1349487), Reynalda Keh de Jesus (14231579), Asra Mirza (1427602), Payal Sheth (3875491), Haifeng Tang (488592), Jin Wu (216487), Todd Black (1882981), Jing Su (23377), Yuriko Root (14231576), Rumin Zhang (2729599), Shuzhi Dong (2352922), Emma R. Parmee (298242), Haiqun Tang (2127373), Daniel F. Wyss (2177280), Inhou Chu (2026375), Charles Garlisi (4397194), Hai-Young Kim (156469), Lianzhu Liang (2276707), William K. Hagmann (1370268), Donald Chu (14231585), Artjohn Villafania (6917033), Guoqing Li (23674), Ronald Painter (2646250), Edward DiNunzio (12293994), Ann E. Weber (1416991)   +43 more
core   +3 more sources

beta-lactamase-inhibitors [PDF]

, 2022
Archive of beta-lactamase-inhibitors containing sub-folders named after each compound and its net charge. Every compound's folder contains a total of 20 files distributed into three sub-directories reporting QM (QM/), FF (FF/), and MD (MD ...
Giuliano Malloci (2060875), Silvia Gervasoni (6169202), Andrea Bosin (6743129), Helen I. Zgurskaya (3093648), Attilio Vittorio Vargiu (2358538), Paolo Ruggerone (247673)   +5 more
core   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms. [PDF]

Antibiotics (Basel), 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol
Bianco G, Gaibani P, Comini S, Boattini M, Banche G, Costa C, Cavallo R, Nordmann P.   +7 more
europepmc   +2 more sources

New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review [PDF]

Journal of Clinical Medicine
Fumio Ōtsuka, Hideharu Hagiya, Kazuyoshi Gotoh   +2 more
exaly   +2 more sources

Antibiotic use in Australian and Swedish primary care: a cross-country comparison

Scandinavian Journal of Primary Health Care, 2022
Objective Antimicrobial resistance is a growing worldwide problem and is considered to be one of the biggest threats to global health by the World Health Organization.
Konny Andersson, Mieke van Driel, Katarina Hedin, Samantha Hollingworth, Gregory Merlo   +4 more
doaj   +1 more source

Clinical Outcomes of Non-carbapenem Treatment for Urinary Tract Infections Caused by Extended-spectrum β-lactamase-producing [PDF]

Childhood Kidney Diseases, 2021
Purpose The purpose of this study was to investigate the clinical outcomes of non-carbapenem treatment for urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) in young children.
Eunae Kim, Yo Han Ahn, Jung Won Lee, Eujin Park   +3 more
doaj   +1 more source

Treatment in Infections by Enterobacterales Producing Extended Spectrum Betalactamase. Systematic Review

Kasmera, 2021
Extended spectrum beta-lactamases producing Enterobacterales have become pandemic worldwide representing a major public health threat due to poor outcomes and high mortality associated with infections by these bacteria, consequently it is essential to ...
Carli Samira Aziz Delgado, José Andrés Mendoza Gaviria   +1 more
doaj   +1 more source

Functional Dynamics of Substrate Recognition in TEM Beta-Lactamase

Entropy, 2022
The beta-lactamase enzyme provides effective resistance to beta-lactam antibiotics due to substrate recognition controlled by point mutations. Recently, extended-spectrum and inhibitor-resistant mutants have become a global health problem.
Chris Avery, Lonnie Baker, Donald J. Jacobs   +2 more
doaj   +1 more source

Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor

Nature Communications, 2020
Beta-lactam antibiotics and beta-lactamase inhibitors compete for the same binding site on beta-lactamases; thus, mutations that increase beta-lactamase activity likely increase also susceptibility to the inhibitor. Here, Russ et al.
Dor Russ, Fabian Glaser, Einat Shaer Tamar, Idan Yelin, Michael Baym, Eric D. Kelsic, Claudia Zampaloni, Andreas Haldimann, Roy Kishony   +8 more
doaj   +1 more source